Back to resultsExpanded Access for IMMU-132
Primary Purpose
Metastatic Triple-Negative Breast Carcinoma
Status
Approved for marketing
Phase
Locations
Study Type
Expanded Access
Intervention
IMMU-132
Sponsored by
About this trial
This is an expanded access trial for Metastatic Triple-Negative Breast Carcinoma
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04320693
Brief Title
Expanded Access for IMMU-132
Official Title
Expanded Access for IMMU-132
Study Type
Expanded Access
2. Study Status
Record Verification Date
April 2020
Overall Recruitment Status
Approved for marketing
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gilead Sciences
4. Oversight
5. Study Description
Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Triple-Negative Breast Carcinoma
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
IMMU-132
Other Intervention Name(s)
Sacituzumab Govitecan
Intervention Description
IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
12. IPD Sharing Statement
Learn more about this trial
Expanded Access for IMMU-132
We'll reach out to this number within 24 hrs